Insider · CIK 0001920399
Jiandong Xu
Files at ESLA (Estrella Immunopharma, Inc.), SMNR (Denali Capital Acquisition Corp.). First filing Apr 29, 2026, latest Apr 29, 2026.
In brief
Jiandong Xu files SEC Form 4 as CFO and 10% owner at ESLA (Estrella Immunopharma, Inc.), and also at SMNR (Denali Capital Acquisition Corp.). Since Apr 29, 2026, Jiandong Xu has reported 1 open-market buy worth $2,594 and 0 open-market sells worth $0, the latest filed on Apr 29, 2026.
A track record needs three past buys with six months of prices behind them; Jiandong Xu has 0, so none is measured yet.
The newest scored trade: bought $2,594 of ESLA on Sep 11, 2025, filed Apr 29, 2026, scored 17 (weak). In the last 12 months: 1 buy worth $2,594 and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ESLA: Estrella Immunopharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 17Weak | ESLAbuy Estrella Immunopharma, Inc. | $2,594 2,100 shares | +1% | - |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | ESLA Estrella Immunopharma, Inc. | MOption exercise Common Stock, par value $0.0001 per share | +100,000 | $0.82 | $82k | 365,488 | Aug 25, 2026 |
| Aug 18, 2026 | ESLA Estrella Immunopharma, Inc. | MOption exercise Incentive Share Optionderivative | -100,000 | - | - | 390,796 | Aug 25, 2026 |
| Sep 11, 2025 | ESLA Estrella Immunopharma, Inc. | POpen-market purchase Common Stock, par value $0.0001 per share | +100 | $1.04 | $104 | 264,588 | Apr 29, 2026 |
| Sep 22, 2025 | ESLA Estrella Immunopharma, Inc. | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Spouse | +1,000 | $1.16 | $1,160 | 16,700 | Apr 29, 2026 |
| Oct 7, 2025 | ESLA Estrella Immunopharma, Inc. | POpen-market purchase Common Stock, par value $0.0001 per share | +1,000 | $1.33 | $1,330 | 265,488 | Apr 29, 2026 |
| Oct 30, 2024 | ESLA Estrella Immunopharma, Inc. | AGrant or award Incentive Share Optionderivative | +490,796 | - | - | 490,796 | Feb 14, 2025 |
| Oct 30, 2024 | ESLA Estrella Immunopharma, Inc. | AGrant or award Nonstatutory Share Optionderivative | +509,204 | - | - | 509,203 | Feb 14, 2025 |
| Aug 30, 2024 | SMNR Denali Capital Acquisition Corp. | SOpen-market sale Class B Ordinary Sharesderivativeindirect: See footnote | -500,000 | - | - | 1,432,500 | Sep 16, 2024 |
Questions about Jiandong Xu
Answered from the filings on this page, as of the latest one.
Is Jiandong Xu buying or selling?
In the last 12 months Jiandong Xu reported 1 open-market buy worth $2,594 and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $2,594 of ESLA on Sep 11, 2025. Grants, option exercises and tax withholding are not counted.
How did Jiandong Xu's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jiandong Xu has 0.
Where does Jiandong Xu file Form 4?
Jiandong Xu has filed Form 4 at ESLA (Estrella Immunopharma, Inc.) as Chief Financial Officer; SMNR (Denali Capital Acquisition Corp.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.